Revlimid Data Could Support First-Line Use In Multiple Myeloma
This article was originally published in The Pink Sheet Daily
Executive Summary
Higher survival rate is seen with Revlimid in combination with lower-dose dexamethasone compared to use with a higher dose of the steroid.